SUMMARY In a prospective study of 176 patients in whom polymyalgia rheumatica (PMR) or giant cell arteritis (GCA) Despite the risk of serious side effects most clinicians give corticosteroid treatment for patients with PMR, and this is considered mandatory if there is evidence of GCA. There is no evidence that corticosteroids reduce the duration of the disease.3 The usual starting dose for those with PMR alone is 10-20 mg prednisolone daily and for the patients with evidence of GCA 40-60 mg daily. Differences of opinion arise in deciding the initial regimen for patients with symptoms of PMR alone who have a positive arterial biopsy. Should these patients be treated with the higher doses of corticosteroids? Serious corticosteroid side effects do occur, particularly in those with GCA started on higher doses.4-7 The problem therefore is in deciding on the initial dose and for how long treatment should continue.8
Polymyalgia rheumatica (PMR) is a well recognised clinical syndrome occurring usually in patients over the age of 55 years, who experience pain and incapacitating morning stiffness in the shoulder and pelvic girdles associated with variable systemic symptoms and a raised erythrocyte sedimentation rate (ESR). The underlying pathological abnormality in PMR is not known, although the association with giant cell arteritis (GCA) is well established; up to 40% of patients with symptoms of PMR have arteritis in temporal artery biopsy specimens.' Occult GCA could therefore be present in all or there could be more than one cause of PMR. Inflammatory arthritis occurs in some cases of PMR2 and GCA.
Despite the risk of serious side effects most clinicians give corticosteroid treatment for patients with PMR, and this is considered mandatory if there is evidence of GCA. There is no evidence that corticosteroids reduce the duration of the disease.3 The usual starting dose for those with PMR alone is 10-20 mg prednisolone daily and for the patients with evidence of GCA 40-60 mg daily. Differences of opinion arise in deciding the initial regimen for patients with symptoms of PMR alone who have a positive arterial biopsy. Should these patients be treated with the higher doses of corticosteroids? Serious corticosteroid side effects do occur, particularly in those with GCA started on higher doses.4-7 The problem therefore is in deciding on the initial dose and for how long treatment should continue.8
Accepted for publication 12 Table 2) . Six of those with visual symptoms at presentation were started on 30-60 mg prednisolone daily, and some patients with PMR started 5-9 mg daily. The corticosteroid dose was regulated with an aim of keeping the patient's symptoms suppressed and the ESR below 30 mm/h. When this was achieved, the dose of prednisolone was decreased by I mg at monthly intervals for those receiving 10 mg a day or less. In those taking higher doses the initial reduction was more rapid as long as the symptoms remained in remission.
Of those with a clinical diagnosis of PMR alone, starting on 10 mg prednisolone daily, fewer needed an increase in dose to control symptoms than those starting on less than 10 mg daily (X2 with Yates's correction = 5-3, p<0-025). Of those with a clinical diagnosis of GCA starting on 20 mg prednisolone daily fewer needed an increase in dose to control symptoms than those starting on 10 mg or less (X2 with Yates's correction = 13-1, p<0-001). Only 7 patients with PMR alone, 5 with mixed PMR/GCA, and 8 with GCA alone required daily doses of prednisolone in excess of 10 mg for longer than one year.
Corticosteroids have been withdrawn from 72 patients after a mean of 31 months of treatment (range 3-103 months), of whom 30 relapsed (Fig. 1) . All relapses occurred within 21 months of withdrawal. There was no significant difference in the mean length of pretreatment symptoms, duration of treatment, starting dose of prednisolone, initial ESR, or haemoglobin between 19 patients with PMR alone who relapsed and 17 who had been off treatment longer than 2 years (Table 3) . Similarly there were no significant differences between 11 patients with GCA who relapsed and 8 who had been off treatment longer than 2 years (Table 3) .
Second and even third attempts at withdrawal were made in 12 of the 30 patients who had relapsed at the initial attempt, of whom 8 remain in remission. Ninety-three patients still need corticosteroids; 5 have required treatment for longer than 10 years.
Six patients were not given corticosteroid treatment. They were all seen early on in the study period. In 3 cases the patients and their family doctors gave a consistent story of polymyalgia rheumatica over a period of months associated with a raised ESR. However, symptoms, signs, and ESR were settling by the time they attended and continued to do so without additional treatment. In 3 others with PMR alone the use of nonsteroidal There is disagreement over the dose of corticosteroids used to treat patients with symptomatic GCA with or without concurrent PMR. Studies established the value of corticosteroids in reducing the incidence of blindness. 15 6 The initial doses used varied from 10 to 50 mg prednisolone and 100 to 300 mg cortisone daily. Paulley et al. 7 found prednisolone 20 mg daily effective and only occasionally found it necessary to use larger doses. Recent recommendations on starting treatment, however, have emphasised total daily doses of prednisolone around 60 mg.5-' 18 Despite the intention of reducing dosage over a few weeks or months it is inevitable that some patients remain on relatively high maintenance doses (10 mg prednisolone or greater), perhaps unnecessarily.7 Although there is a clinical impression that larger doses of corticosteroid are needed to control the symptoms and signs of GCA than for PMR alone, there is no evidence that 60 mg of prednisolone daily as an initial dose is any better than 20 mg in preventing complications of GCA. In patients treated with large doses of corticosteroids further visual loss has occurred after starting treatment.'9 Corticosteroids probably have complex effects on coagulation and have been shown to inhibit the synthesis of prostacyclin.20 Topical and occasionally high-dose systemic corticosteroids may cause an increase in intraocular pressure.2' Perhaps high doses occasionally have a deleterious effect on a critical vascular state. Corticosteroids are thought to be a possible cause of necrotising arteritis in patients with rheumatoid arthritis treated with high doses. 22 This speculative suggestion highlights the uncertain mechanism by which corticosteroids protect against visual loss. Repeat biopsies during and after treatment and long after clinical signs and symptoms have disappeared sometimes show an active arteritis.' We believe our experience provides evidence that a starting dose of 20 mg prednisolone daily is adequate for most patients with GCA and may avoid more prolonged periods at higher dosage.
An early study of PMR before corticosteroids were used in treatment suggested wide variation in duration of the disease, with a mean of 7 years.23 There have been suggestions that treatment is usually necessary for only 2 to 3 years5 19 and that relapse after stopping treatment is rare.24 Our patients have shown a wider variation in duration of treatment necessary to suppress symptoms, which presumably reflects the period of active disease and agrees with the experience of others. [25] [26] [27] Relapse after corticosteroid withdrawal was common in our patients, and it was not possible to find a clinical feature that would identify those at risk. We suggest that patients are followed up for at least 2 years after corticosteroid withdrawal, with particular attention to symptoms. Balanced against the relief of symptoms and prevention of serious complications, the incidence of possible corticosteroid side effects has been acceptably small.
We believe that regular and personal follow-up of patients makes possible the use of the minimum effective dose of corticosteroids, and no exact schedule of duration of treatment should be recommended. 
